A recent study from the Institute for Genomics and Systems Biology, University of Chicago and Argonne National Laboratory, Chicago, Illinois-IL 60637, USA; Department of Human Genetics, University of Chicago, Chicago, IL 60637, USA; and Section on Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL 60637, USA shows that “SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub…” This study was published in the Apr 14 2014 issue of the journal “Cancer Cell“ (one of the top journal in Cancer Biology with an IF of of 24.755) by Prof. White, Li G and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for Renal cancer: Agaricus blazei Murill (AbM), a medicinal mushroom, suppresses the expression of SPOP via up regulation of its target gene.
This study suggests, for the first time, that Agaricus blazei Murill (AbM), by increasing the expression of its target gene, it may suppress the expression of E3 ubiquitin ligase SPOP. Thereby, it may increase the expression of tumor suppressor genes PTEN, ERK phosphatases, the proapoptotic molecule Daxx, and p53. Thus, pharmacological formulations encompassing “Agaricus blazei Murill” may be used to treat cancers, including renal cancer.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Natural product-based therapy for Renal cancer: Agaricus blazei Murill (AbM), a medicinal mushroom, suppresses the expression of SPOP via up regulation of its target gene, 28/May/2014, 14.21, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation